Our Products in Europe
All of our products are prescription-only medicines (POM). If more information is required, please refer to the local SPC or PIL.

ABILIFY® (aripiprazole)

ABILIFY contains the active substance aripiprazole. It is available in different forms (tablets, oral solution and orodispersible tablets).

ABILIFY MAINTENA® (aripiprazole)

ABILIFY MAINTENA contains the active substance aripiprazole. It is available as a powder and solvent to be made into a suspension for injection.

SAMSCA® (tolvaptan)

SAMSCA contains the active substance tolvaptan. It is available as a tablet.

JINARC® (tolvaptan)

JINARC contains the active ingredient tolvaptan and it is available as a tablet.

SPRYCEL® (dasatinib)

SPRYCEL contains the active substance dasatinib and is available as tablets of various strengths. The medicine can only be obtained with a prescription. The Marketing Authorisation Holder of the drug is Bristol-Myers Squibb Pharma EEIG.

Pletal® (cilostazol)

Pletal contains the active substance cilostazol. It is available as a tablet. ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their relevant local bodies.

Date of preparation: January 2019

最新1本道dvd更新 1本道Av在線Reference OPEL/0119/COMS/1000w